Search results for "CD40"

showing 10 items of 122 documents

Perpetual proliferation of LYT-1 cells requires repetitive signals for IL-2 receptor induction by antigen-presenting cells.

1984

Abstract T cell lines with specificity for bovine insulin and ovalbumin were maintained by serial stimulation with antigen presented on irradiated syngeneic spleen cells, alternating 3 days later with subculture in IL-2 containing medium (CM). When the cultures were repetitively split in CM, with concomitant dilution of antigen-presenting cells, a gradual loss of proliferative capacity of the cells in the presence of CM was observed. Absorption studies revealed a 20-fold reduction of IL-2 receptors on the surface of T blasts assayed 12 days after antigenic stimulation as compared with day 5 blasts. This decrement in the number of IL-2 acceptor sites reflected an actual decrease in cell surf…

Time FactorsCell divisionOvalbuminT cellT-LymphocytesImmunologyReceptors Antigen T-CellLymphocyte ActivationAbsorptionCell LineMiceAntigenmedicineImmunology and AllergyCytotoxic T cellAnimalsIL-2 receptorAntigensReceptors ImmunologicReceptorAntigen-presenting cellCD40biologyReceptors Interleukin-2HematologyMolecular biologymedicine.anatomical_structureImmunologybiology.proteinInterleukin-2SpleenImmunobiology
researchProduct

Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protect…

1999

Transcutaneous immunization (TCI) using ligands of Toll-like receptors (TLRs) and cytotoxic T-lymphocyte (CTL) epitopes lead to the induction of potent T-cell responses. To characterize the efficacy of TCI-mediated CTL activation, we monitored the frequency and functional activity of specific CTL induced with TCI using the ovalbumin-derived epitope SIINFEKL composed in creme containing the synthetic TLR7 ligand R-837. We found that the frequency and activity decayed rapidly 10 d post-TCI. Consistently, no significant memory T-cell formation was detectable. In a prophylactic vaccination setting, TCI was protective against a lethal challenge with ovalbumin expressing EG.7 thymoma cells when t…

Time Factorsmedicine.drug_classT cellmedicine.medical_treatmentBiologyMonoclonal antibodyAdministration CutaneousLymphocyte ActivationEpitopeMiceAntigenCell Line TumorNeoplasmsmedicineImmunology and AllergyCytotoxic T cellAnimalsCD40 AntigensImiquimodGeneral MedicineImmunotherapyMice Inbred C57BLSurvival RateCTL*medicine.anatomical_structureImmunizationImmunologyAminoquinolinesImmunizationImmunotherapyImmunologic MemoryNeoplasm TransplantationT-Lymphocytes CytotoxicClinical reviews in allergyimmunology
researchProduct

Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.

1997

Abstract The current study was carried out to elucidate the immunoregulatory changes induced by venom immunotherapy (VIT) in bee or wasp allergic subjects. All subjects included in this study had a history of severe systemic allergic reactions to stings of the respective insect as well as positive skin tests with the respective venom or venom-specific IgE in the sera. Parameters assessed in peripheral blood mononuclear cells (PBMC) before and after initiation of VIT (rush therapy reaching a maintenance dose of 100 micrograms venom injected subcutaneously within 1 week) were expression of CD3, CD4, CD8, CD45RA, CD45RO, interleukin (IL)-2 receptor (R) alpha, IL-4R, IL-12R, Fc epsilon RII, CD4…

Time Factorsmedicine.medical_treatmentImmunologyCD40 LigandDown-RegulationVenomWasp VenomsImmunoglobulin ELigandsLymphocyte ActivationPeripheral blood mononuclear cellInterferon-gammaTh2 CellsAntigens CDT-Lymphocyte SubsetsmedicineImmunology and AllergyHumansLymphocyte CountRNA MessengerCD40 AntigensCD40Membrane GlycoproteinsbiologyReceptors IgEInterleukinAntibodies MonoclonalInsect Bites and StingsReceptors InterleukinAllergensTh1 CellsInterleukin-10Receptors Interleukin-4Interleukin 10Bee VenomsCytokineDesensitization ImmunologicImmunologyAntigens Surfacebiology.proteinInterleukin-4AntibodyEuropean journal of immunology
researchProduct

Physiological activation of the IgH 3' enhancer in B lineage cells is not blocked by Pax-5.

1996

The mouse 3' enhancer contains a high-affinity binding site for the paired box protein Pax-5. Here, we demonstrate by genomic footprinting that the rat 3' enhancer contains a low-affinity binding site for Pax-5, which is occupied in activated splenic B cells. Thus, binding of Pax-5 to the IgH 3' enhancer appears to be evolutionarily conserved in rodents. Analysis of Pax-5 expression in primary B cells demonstrates that Pax-5 remains expressed after 4 days of lipopolysaccharide (LPS) induction, but is down-regulated in 5-day stimulated cells. Similarly, the expression of Pax-5 is down-regulated in vivo in activated large splenocytes, in contrast to small resting cells. Multimerization of the…

Transcriptional Activationcongenital hereditary and neonatal diseases and abnormalitiesanimal structuresImmunologyCD40 LigandDNA FootprintingHeterologousDown-RegulationReceptors Antigen B-CellEnhancer RNAsLymphocyte ActivationMiceGene expressionImmunology and AllergyAnimalsBinding siteEnhancerTranscription factorCells CulturedReporter geneB-LymphocytesCD40Membrane GlycoproteinsbiologyGenes ImmunoglobulinPAX5 Transcription FactorNuclear ProteinsMolecular biologyRatsUp-Regulationbody regionsDNA-Binding ProteinsRepressor ProteinsEnhancer Elements GeneticGene Expression Regulationembryonic structuresbiology.proteinTrans-Activatorssense organsTranscription FactorsEuropean journal of immunology
researchProduct

CD40-Activated B Cells Migrate Towards Secondary Lymphoid Organs And Interact Dynamically With T Cells

2010

TransplantationCD40biologybusiness.industrybiology.proteinMedicineHematologybusinessSecondary lymphoid organsCell biologyBiology of Blood and Marrow Transplantation
researchProduct

Humoral immunotherapy of multiple myeloma: perspectives and perplexities

2010

IMPORTANCE OF THE FIELDS Multiple myeloma (MM) is a hematological malignancy still remaining incurable despite the various therapies available, mainly because of the high fraction of refractory/relapsing cases. Therefore, the development of novel therapeutic approaches is urgently needed to overcome conventional treatment resistance. AREAS COVERED IN THIS REVIEW: In the era of targeted therapies, treatments combining a high specificity for neoplastic cells and the capability to interfere with environmental signals should be regarded as the weapons of choice. Monoclonal antibody (mAb)-based humoral immunotherapy could satisfy both these requirements when applied to MM. Indeed, many of the mo…

medicine.drug_classmedicine.medical_treatmentClinical BiochemistryCD38Monoclonal antibodyAntigens NeoplasmDrug DiscoverymedicineAnimalsHumansMultiple myelomamultiple myeloma; immunotherapyPharmacologyCD40biologybusiness.industryConventional treatmentAntibodies MonoclonalImmunotherapymedicine.diseaseImmunity Humoralmultiple myelomamultiple myeloma humoral immunotherapyHematological malignancyImmunologyMolecular targetsbiology.proteinimmunotherapybusiness
researchProduct

IFN-alpha Stimulates Proliferation and Cytokine Secretion of CD40-Stimulated B Cell Chronic Lymphocytic Leukemia Cells In Vitro

1999

Interferon (IFN)-alpha has a therapeutic effect in several B cell malignancies, including low-grade non-Hodgkin's lymphoma (NHL), multiple myeloma, and hairy cell leukemia, whereas its efficacy in the treatment of B cell chronic lymphocytic leukemia (B-CLL) is rather limited. In the present study, we investigated the effect of IFN-alpha on the biologic functions of B-CLL cells, which were stimulated by cross-linking of the CD40 antigen. In cell samples from 16 B-CLL patients, the addition of IFN-alpha to CD40-stimulated purified B-CLL cells caused a significant increase in [3H]thymidine uptake (p < 0.003). In B-CLL cells maximally activated by CD40 cross-linking and interleukin-2 (IL-2)/IL-…

medicine.medical_specialtyAdoptive cell transferImmunologyNaive B cellAntineoplastic Agentsimmune system diseaseshemic and lymphatic diseasesVirologyInternal medicineTumor Cells CulturedmedicineHumansHairy cell leukemiaCD40 AntigensCells CulturedB cellCD20B-LymphocytesCD40biologyChemistryInterferon-alphaCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellStimulation ChemicalClone CellsEndocrinologymedicine.anatomical_structurebiology.proteinCancer researchCytokinesCytokine secretionDrug Screening Assays AntitumorCD5Cell DivisionJournal of Interferon &amp; Cytokine Research
researchProduct

Therapeutic dosages of oral or transdermal estradiol did not modify sCD40L levels in postmenopausal women.

2008

The CD40/CD40L system is considered a crucial modulator of the inflammatory process underlying the progression and complication of atheroma plaques. The soluble fraction of CD40L (sCD40L) is a reliable indicator of the CD40/CD40L system. Our purpose was to investigate whether a therapeutic dose of estradiol, by either the oral or the transdermal route, was associated with changes in circulating levels of sCD40L. Forty-seven women completed a 4-week course of treatment with either oral estradiol valerate (2 mg/day, 20 women) or transdermal estradiol (50 microg/day, 27 women). Serum levels of sCD40L were measured by conventional enzyme-linked immunosorbent assay. Oral, but not transdermal est…

medicine.medical_specialtyDoseEndocrinology Diabetes and MetabolismCD40 LigandAdministration OralEnzyme-Linked Immunosorbent AssayPharmacologyAdministration CutaneousFollicle-stimulating hormoneEndocrinologyTherapeutic indexInternal medicinemedicineHumansCD40 AntigensTriglyceridesTransdermalmedicine.diagnostic_testEstradiolbusiness.industryTransdermal routeEstradiol valerateObstetrics and Gynecologymedicine.diseaseAtherosclerosisMenopausePostmenopauseEndocrinologyCholesterolFemaleFollicle Stimulating HormoneLipid profilebusinessmedicine.drugGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct

41 SERUM FETUIN A/ALPHA2HS-GLYCOPROTEIN AND CD40 L IN TOAST STROKE SUBTYPES: CORRELATION WITH LABORATORY, CLINICAL VARIABLES AND PROGNOSIS

2008

medicine.medical_specialtyNutrition and DieteticsCD40Clinical variablesbiologybusiness.industryEndocrinology Diabetes and MetabolismMedicine (miscellaneous)medicine.diseaseGastroenterologyFetuinCorrelationInternal medicineImmunologybiology.proteinMedicineCardiology and Cardiovascular Medicinebusinessalpha-2-HS-glycoproteinStrokeNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Induction of dendritic cell maturation and modulation of dendritic cell-induced immune responses by prostaglandins

2000

Dendritic cells (DC) are the most potent antigen-presenting cells of the immune system. In this study we investigated the effects of various prostaglandins (PG) on the stimulatory capacity of DC. DC were generated from peripheral progenitor cells in the presence of IL-4 and GM-CSF and stimulated with IL-1, IL-6 and TNF-alpha on day 7. Simultaneously, PG (PGD(2), PGE(1), PGE(2), PGF(2 alpha), PGI(2)) were added at various concentrations (10(-5) to 10(-9) M) on day 7. In all experiments, PGE(2) had the most potent influence on the maturation of the DC, followed by other PG in the order PGE(1) > PGD(2) > PGF(2 alpha) > PGI(2). In addition, the expression of the surface molecules CD40, CD54, CD…

medicine.medical_specialtymedicine.medical_treatmentDermatologyLymphocyte ActivationProinflammatory cytokinechemistry.chemical_compoundInterferon-gammaAntigens CDInternal medicinemedicineHumansCells CulturedMHC class IIForskolinCD40biologyDose-Response Relationship DrugInterleukin-6Prostaglandin D2Tumor Necrosis Factor-alphaColforsinCell DifferentiationGeneral MedicineDendritic cellDendritic CellsMolecular biologyInterleukin-12Coculture TechniquesEndocrinologyCytokinechemistryBucladesinebiology.proteinProstaglandinsCytokinesInterleukin-2lipids (amino acids peptides and proteins)CD80CD8Interleukin-1
researchProduct